Sernova to Present at the OneMedForum San Francisco 2011 Conference

LONDON, ONTARIO--(Marketwire - Jan. 12, 2011) - Sernova Corp. (TSX VENTURE:SVA), a company focused on product development and commercialization of innovative medical technologies for cell therapies, is pleased to announce that its President & Chief Executive Officer, Dr. Philip Toleikis will present an overview of the company's technology and strategic positioning to a select group of biotech industry investors at the OneMedForumSF 2011, Emerging Company Finance Conference on Wednesday, January 12, 2011 at 2:00 p.m. (PT) at the Sir Francis Drake Hotel in San Francisco, California. 

OneMedForum takes place January 11-13, 2011 in San Francisco, CA during the world's largest gathering of healthcare financiers and executives. The Forum will feature presentations by over 100 of the world's most promising emerging life science public and private companies. In 2010, over 1,000 investors participated in the conference. To learn more about the forum, visit www.onemedplace.com.

Sernova's Cell Pouch System™ is a scalable medical device providing a natural "organ-like" environment for therapeutic cells. Once implanted under the skin, it develops into a tissue-engineered pancreas when infused with islets. The natural environment established by the Cell Pouch System™ is expected to conserve cell number, and promote natural function thereby increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.

About Sernova

Sernova Corp. is a Canadian-based, health-sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin-dependent diabetes, using the novel Cell Pouch System™ and its patented Sertolin™ cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.